Theratechnologies   Report issue

Contributed to NME For profit Phase 1 Phase 4
Founded: Montreal Quebec Canada (1993)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2002
NCT01264497
First Marketed Drug
2010
tesamorelin (egrifta)
First NDA Approval
2010
tesamorelin (egrifta)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Theratechnologies | THERATECHNOLOGIES | Theratechnologies Inc.

Active Ingredients

Marketed Drugs (2)

ibalizumab-uiyk (trogarzo) (2018)

tesamorelin (egrifta) (2010 NDA)

Drugs in Phase 4 Trials (1)

tesamorelin (egrifta) (6 trials)

Drugs in Phase 1 Trials (1)

Sudocetaxel zendusortide (1 trial)

Indications

Approved Indications


 

HIV-Associated Lipodystrophy Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Retinopathy (Phase 4)

HIV Seropositivity (Phase 1)

Lipodystrophy (Phase 3)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Muscular Atrophy (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Retinal Diseases (Phase 4)

Wasting Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 2